Since the New England Journal of Medicine publication on intravenous immune globulin (IVIG) for dermatomyositis late last year, the data have proved a major lift for patient care, offering crucial new insights into how best to manage patients and clues about how to minimize risks.1 The ProDERM trial results also seem to have opened up…
Have you ever wondered who plans the ACR annual meeting, State-of-the-Art (SOTA) Clinical Symposium, Pediatric Rheumatology Symposium (PRSYM) and the ACR Winter Rheumatology Symposium? Who chooses the topics? Who invites the speakers? You may be surprised to hear that it’s ACR members—just like you. These members volunteer for the ACR Committee on Education and/or its…
I was cleaning out an old storage closet in my parents’ house in Florida when I stumbled across some notes I took in medical school. As I leafed through pages and pages of notes filled with doodles and reminders, I found a statement that gave me pause: “Immunology—what is it good for?!” To be honest,…
ACR Convergence 2023 offers so much more than scientific sessions. If you have a special interest in a topic, this is the place to be. Consider these opportunities: Lab Tests Open Meeting Sunday, Nov. 12, 10–11 a.m. PST Location: Sapphire E Room, Hilton San Diego Bayfront Attendees interested in laboratory testing issues are invited to…
The ACR released a new arthroplasty guideline in an effort to remedy significant & detrimental delays faced by osteoarthritis or osteonecrosis patients who require surgical intervention.
Think about it. Most rheumatology labs are stuck in the 1960s. Translational biomarker research looks excellent on paper and in theory. However, many barriers exist from the bench to the bedside. This article highlights this problem for the rheumatology community and proposes practical solutions. Case in Point For an example, let’s examine systemic lupus erythematosus…
The ACR recently released an update on the prevention and treatment of glucocorticoid-induced osteoporosis.1 The guideline, which includes information on the new therapies abaloparatide and romosozumab, emphasizes the importance of shared decision making by patients and clinicians, and also gives information on the importance of sequential therapy after stopping certain osteoporotic prevention therapies. Fracture Prevention…
In late September, 80 rheumatologists, rheumatology professionals and patients living with rheumatic disease convened in Washington, D.C., for the ACR’s annual Advocates for Arthritis conference, where they marshaled in support of legislation that would reduce current barriers to care for patients.
The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.
Recent proposals in the U.S. to bill for electronic communication with our patients could be seen as a refreshing but contested attempt to battle burnout rates in the present era. A fee for electronic communications between patients and clinicians also acknowledges the value of the clinician’s time and expertise. But is this ethical? Discussion Burnout…